MedTrace Logo

Validation of a Combined Symptom and Medication Score in Patients Suffering From Allergic Rhinoconjunctivitis

NCT04071249 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2020-08-26

No results posted yet for this study

Summary

This study is a mere data collection without predefined intervention. Patients aged 12 years or older who suffer from allergic rhinitis induced by house dust mites, tree pollen or grass pollen and who are treated exclusively with anti-allergic medication may take part. The treatment follows the normal medical practice in accordance with national medical guidelines. During the study, data are collected during 3 visits with regard to allergic complaints of a patient and intake of anti-allergic medication. The first visit takes place before allergen exposure, the second visit at the peak of allergen exposure and the third visit after allergen exposure. The allergen exposure is defined as the enhanced exposure to house dust mites during the heating period or the respective pollen season. During the visits, the patients will be asked to complete questionnaires with regard to their quality of life and rhinitis control. Furthermore during allergen exposure, the patients document their allergic complaints and intake of anti-allergic medication in a diary. The diary entries are used to generate the Combined Symptom and Medication Score (CSMS) which will be validated in the course of this study. The validation will be performed by comparing the CSMS with the scores from the already validated questionnaires.

Conditions

  • Rhinoconjunctivitis, Allergic

Sponsors & Collaborators

  • ClinNovis GmbH

    lead OTHER

Principal Investigators

  • Ralph Moesges, Prof. Dr. · ClinNovis GmbH, Genter Str. 7, 50672 Cologne, Germany

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2020-08-25
Completion
2020-08-25

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071249 on ClinicalTrials.gov